See more : National Bank of Canada (NA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Rani Therapeutics Holdings, Inc. (RANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rani Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Thanachart Capital Public Company Limited (TCAP.BK) Income Statement Analysis – Financial Results
- Atlantic Coastal Acquisition Corp. (ACAHW) Income Statement Analysis – Financial Results
- Clio Infotech Limited (CLIOINFO.BO) Income Statement Analysis – Financial Results
- Winland Holdings Corporation (WELX) Income Statement Analysis – Financial Results
- Alkane Resources Limited (ALK.AX) Income Statement Analysis – Financial Results
Rani Therapeutics Holdings, Inc. (RANI)
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.72M | 462.00K | 979.00K |
| Cost of Revenue | 822.00K | 1.31M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -822.00K | -1.31M | 2.72M | 462.00K | 979.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.62M | 36.61M | 26.48M | 12.04M | 24.58M |
| General & Administrative | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Cost & Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Interest Income | 3.30M | 1.25M | 89.00K | 63.00K | 423.00K |
| Interest Expense | 5.09M | 1.07M | 466.00K | 124.00K | 10.00K |
| Depreciation & Amortization | 822.00K | 1.31M | 497.00K | 589.00K | 564.00K |
| EBITDA | -65.28M | -60.89M | -52.08M | -15.96M | -26.01M |
| EBITDA Ratio | 0.00% | 0.00% | -1,895.84% | -3,439.83% | -2,663.74% |
| Operating Income | -66.10M | -63.45M | -51.60M | -16.54M | -27.07M |
| Operating Income Ratio | 0.00% | 0.00% | -1,899.12% | -3,580.95% | -2,764.56% |
| Total Other Income/Expenses | -1.78M | 177.00K | -1.45M | -124.00K | 478.00K |
| Income Before Tax | -67.88M | -63.27M | -53.05M | -16.67M | -26.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,952.41% | -3,607.79% | -2,715.73% |
| Income Tax Expense | 0.00 | 70.00K | 41.00K | 35.00K | 10.00K |
| Net Income | -33.97M | -63.34M | -53.09M | -16.70M | -26.60M |
| Net Income Ratio | 0.00% | 0.00% | -1,953.92% | -3,615.37% | -2,716.75% |
| EPS | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| Weighted Avg Shares Out | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
| Weighted Avg Shares Out (Dil) | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
Source: https://incomestatements.info
Category: Stock Reports